ICLR

+ Watchlist + Portfolio

ICON plc

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $172.49
52-Week Range: $66.57 – $203.91
Market Cap: $13.45B
P/E (TTM): 264.04
EPS (TTM): 0.66
Dividend Yield: —

Advanced Metrics

Price/Book: 1.43
PEG Ratio: 0.56
Return on Equity: 0.29%
Return on Assets: 0.97%
Gross Margin: 23.91%
Operating Margin: 9.41%
Profit Margin: 0.33%
Current Ratio: 0.95
Debt/Equity: 0.38
Total Debt: $3.53B
Free Cash Flow: $622.65M
Revenue Growth: 1.20%
Earnings Growth: -63.30%
Enterprise Value: $15.91B

ICLR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$7.74B	$8.05B	$8.19B	$8.25B
Cost of Revenue	$5.53B	$5.71B	$5.82B	$6.08B
Gross Profit	$2.21B	$2.35B	$2.37B	$2.18B
Selling, General & Admin	$778.75M	$768.56M	$728.35M	$780.14M
Operating Expenses	$1.35B	$1.35B	$1.22B	$1.16B
Operating Income	$866.08M	$994.23M	$1.15B	$1.01B
EBITDA	$1.35B	$1.47B	$1.50B	$823.57M
Pretax Income	$567.85M	$572.98M	$803.76M	$252.47M
Income Tax	$59.41M	$18.39M	$64.63M	$23.13M
Net Income	$505.30M	$554.21M	$739.13M	$229.34M
Diluted EPS	6.13	7.40	9.53	2.90
Diluted Shares	82.54M	82.72M	83.03M	78.97M

ICLR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$288.77M	$378.10M	$538.78M	$647.29M
Receivables	$2.80B	$2.78B	$2.60B	$2.75B
Current Assets	$3.23B	$3.29B	$3.28B	$3.50B
Total Assets	$17.19B	$16.86B	$16.63B	$16.27B
Current Liabilities	$2.69B	$2.73B	$2.64B	$3.20B
Long-Term Debt	$4.60B	$3.67B	$3.40B	$2.87B
Total Debt	$4.83B	$3.94B	$3.60B	$3.56B
Total Liabilities	$8.69B	$7.65B	$7.19B	$7.08B
Retained Earnings	$1.82B	$2.40B	$2.64B	$2.12B
Shareholders' Equity	$8.50B	$9.21B	$9.44B	$9.19B
Working Capital	$538.47M	$556.88M	$639.68M	$305.50M
Net Debt	$4.37B	$3.40B	$2.89B	$2.76B

ICLR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$563.32M	$1.16B	$1.29B	$1.04B
Capital Expenditure	-$142.16M	-$140.69M	-$168.06M	-$174.21M
Free Cash Flow	$421.15M	$1.02B	$1.12B	$861.99M
Depreciation & Amortisation	$569.51M	$585.95M	$488.50M	$383.00M
Stock-Based Compensation	$70.52M	$55.67M	$45.87M	$102.04M
Investing Cash Flow	-$145.87M	-$226.65M	-$266.79M	-$187.53M
Financing Cash Flow	-$864.17M	-$844.04M	-$837.18M	-$771.26M
Share Repurchases	-$99.98M	$0.00	-$500.00M	-$750.00M
Net Change in Cash	-$446.73M	$90.33M	$182.68M	$77.42M

ICLR Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$2.04B	$2.08B	$2.19B	$2.03B	$2.06B
Cost of Revenue	$1.46B	$1.54B	$1.69B	$1.56B	$1.58B
Gross Profit	$583.33M	$545.46M	$500.89M	$477.93M	$479.29M
Selling, General & Admin	$205.01M	$197.05M	$179.70M	$200.60M	$194.32M
Operating Expenses	$302.72M	$296.08M	$270.52M	$290.93M	$285.08M
Operating Income	$280.61M	$249.38M	$230.37M	$187.00M	$194.21M
EBITDA	$330.71M	-$122.12M	$10.43M	$265.89M	$231.75M
Pretax Income	$182.84M	-$271.39M	-$120.50M	$127.56M	$92.20M
Income Tax	-$20.67M	$12.79M	-$10.36M	$22.81M	$19.61M
Net Income	$203.52M	-$284.18M	-$110.14M	$104.75M	$72.58M
Diluted EPS	2.56	-3.67	1.93	1.36	0.94
Diluted Shares	79.55M	77.37M	77.31M	77.26M	77.37M

ICLR Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$390.40M	$468.89M	$647.29M	$765.16M	$928.38M
Receivables	$2.78B	$2.80B	$2.75B	$2.70B	$2.71B
Current Assets	$3.31B	$3.41B	$3.50B	$3.61B	$3.75B
Total Assets	$16.60B	$16.51B	$16.27B	$16.32B	$16.40B
Current Liabilities	$2.56B	$3.22B	$3.20B	$3.17B	$3.93B
Long-Term Debt	$3.38B	$2.88B	$2.87B	$2.87B	$2.11B
Total Debt	$3.55B	$3.53B	$3.56B	$3.51B	$3.49B
Total Liabilities	$7.05B	$7.17B	$7.08B	$7.02B	$7.02B
Retained Earnings	$2.56B	$2.31B	$2.12B	$2.23B	$2.30B
Shareholders' Equity	$9.56B	$9.33B	$9.19B	$9.30B	$9.38B
Working Capital	$752.44M	$189.43M	$305.50M	$437.80M	-$186.02M
Net Debt	$3.02B	$2.94B	$2.76B	$2.63B	$2.46B

ICLR Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$146.20M	-$146.20M	$234.16M	$167.01M	$281.27M
Capital Expenditure	-$32.28M	-$53.70M	-$59.33M	-$30.77M	-$42.42M
Free Cash Flow	$113.92M	-$113.92M	$174.83M	$136.24M	$238.85M
Depreciation & Amortisation	$97.72M	-$97.72M	$90.83M	$90.33M	$90.77M
Stock-Based Compensation	$15.25M	-$15.25M	$29.51M	$27.57M	$18.46M
Investing Cash Flow	-$38.21M	$38.21M	-$55.94M	-$39.44M	-$108.34M
Financing Cash Flow	-$255.86M	$255.86M	-$5.79M	-$6.36M	-$8.12M
Share Repurchases	-$250.00M	$250.00M	$0.00	$0.00	$0.00
Net Change in Cash	-$147.87M	$147.87M	$172.43M	$121.21M	$164.82M

Market Snapshot

About

ICON plc is a global provider of drug development solutions and services to pharmaceutical, biotechnology, and medical device companies. The company offers a full range of clinical research organization (CRO) services including clinical trial management, data management, biostatistics, regulatory consulting, and central laboratory services. ICON has broad therapeutic expertise and conducts clinical trials across all phases of development in multiple regions worldwide. The company has grown through both organic expansion and strategic acquisitions, becoming one of the largest CROs serving the life sciences industry.